HANGZHOU TIGERMED CONSULTING (300347) H2 2025 earnings summary

Executive summary

• Provided comprehensive clinical trial and laboratory services for global pharmaceutical and medical device innovation, maintaining industry leadership and expanding international presence.

• Achieved significant progress in digitalization and AI-driven clinical research, with proprietary AI platforms enhancing efficiency and compliance.

• Continued strategic acquisitions, including the purchase of Japan's Micron, to strengthen global service capabilities.

Financial highlights

• 2025 revenue reached ¥6.83 billion, up 3.48% year-over-year; net profit attributable to shareholders was ¥887.89 million, up 119.15%.

• Gross margin declined to 26.53% from 33.27% last year; main business gross profit was ¥1.78 billion, down 17.31%.

• Operating cash flow was ¥1.12 billion, up 1.92% year-over-year.

• Basic and diluted EPS were both ¥1.04, up 121.28% year-over-year.

• R&D investment was ¥257.64 million, accounting for 3.77% of revenue.

Outlook and guidance

• Anticipates continued recovery in domestic biopharma demand and further international expansion, with digital and AI capabilities as key growth drivers.

• Expects improvement in domestic clinical operations as industry recovers and project backlog increases.

• Plans to maintain stable dividends and continue share repurchases to enhance shareholder value.